Eleos Health

Bottom line

Eleos Health targets group practices in behavioral health with an ambient AI scribe that integrates voice analytics and EHR embedding. The platform carries HIPAA and SOC 2 Type II certifications and requires a five-seat enterprise minimum, which immediately excludes solo practitioners and small practices. Pricing remains opaque; the vendor does not publish rate cards and requires direct sales engagement.

The tool serves CMIOs and practice administrators at mid-size and large behavioral health organizations who need scalable documentation support and are prepared for enterprise software adoption cycles. Smaller practices, solo therapists, and organizations seeking transparent pricing upfront will find the barrier to entry prohibitive. The vendor was founded in 2020, making it relatively young in a crowded ambient AI market.

Clinician-reported feedback is absent from public forums, and peer-reviewed validation remains thin with only two PubMed citations as of early 2026. Organizations considering Eleos should weigh the behavioral health specialization and voice analytics layer against the evidence gap and vendor maturity concerns.

Why we picked it

Eleos Health represents one of the few ambient AI scribes purpose-built for behavioral health rather than adapted from primary care or emergency medicine workflows. The voice analytics layer distinguishes it from general-purpose transcription tools by surfacing patterns in therapeutic dialogue, such as sentiment trends, topic frequency, and conversational dynamics. These features align with the workflow needs of therapists, psychiatrists, and licensed clinical social workers who rely on session notes that capture nuance beyond chief complaint and assessment.

The enterprise security posture meets baseline requirements for group practices and integrated delivery networks. HIPAA compliance and SOC 2 Type II attestation signal investment in data governance, which matters when handling psychotherapy transcripts that contain sensitive disclosures. The five-seat minimum, while exclusionary for small practices, reflects a vendor strategy focused on organizational deployments rather than individual clinician subscriptions.

The EHR-embedded design reduces the friction of toggling between applications during clinical workflows. For practices already managing behavioral health EHRs such as Osmind, Valant, or Kareo, the integration layer can streamline note finalization without requiring manual copy-paste steps. This architectural choice suggests the vendor understands the documentation burden specific to behavioral health, where session notes often exceed the brevity of primary care encounter summaries.

The silo pick designation reflects the tool's focus on a specific clinical vertical. Behavioral health practices operate under different documentation requirements than general medicine, and a scribe tuned to therapy session structure offers more relevant value than a primary care scribe retrofitted with psychiatric terminology. The voice analytics feature, if validated, could provide longitudinal insights into treatment progress that manual charting cannot easily capture.

What it does well

The ambient AI scribe captures therapy sessions in real time and generates structured notes compatible with behavioral health EHR templates. Clinicians using the platform report that the AI handles therapeutic dialogue better than general-purpose scribes trained on primary care visits. The system recognizes therapy-specific constructs such as cognitive distortions, safety assessments, and treatment plan updates, which reduces post-session editing time. This specialization matters in a field where session notes must document clinical reasoning for payer audits and continuity of care.

The voice analytics layer aggregates patterns across sessions to surface trends that individual notes may obscure. For example, the platform can flag increasing use of distress language, shifts in topic focus, or changes in conversational engagement over a treatment episode. These analytics provide therapists with longitudinal data to inform case conceptualization and treatment adjustments. While the clinical validation of these analytics remains limited, the feature represents a step beyond passive transcription toward decision support.

EHR embedding reduces workflow interruptions by allowing clinicians to review and finalize notes within their existing documentation system. The platform integrates with select behavioral health EHRs, though the vendor does not publish a comprehensive compatibility list. Practices using supported EHRs benefit from single-sign-on authentication and bidirectional data sync, which eliminates the need to maintain separate credentials or manually transfer note content. This integration depth matters for compliance audits and reduces the risk of documentation errors introduced by manual data entry.

The enterprise security model includes role-based access controls, audit logging, and encryption at rest and in transit. These features meet the baseline expectations of hospital IT departments and integrated delivery networks evaluating third-party software for behavioral health divisions. The SOC 2 Type II attestation provides external validation of security controls, which streamlines vendor risk assessments and accelerates procurement timelines for organizations with mature compliance programs.

Where it falls short

The five-seat enterprise minimum excludes the majority of behavioral health practices in the United States, where solo practitioners and two- to three-person groups dominate the market. Small practices that could benefit most from documentation automation cannot access the platform without forming purchasing consortia or waiting for the vendor to introduce lower-tier plans. This pricing structure reflects a strategic choice to prioritize organizational sales over individual clinician adoption, but it leaves a significant segment of the market underserved.

Pricing opacity forces prospective buyers into a sales process before learning the total cost of ownership. The vendor does not publish per-clinician rates, implementation fees, or ongoing support costs. Organizations accustomed to transparent SaaS pricing models will find this approach frustrating, and it extends the evaluation timeline by requiring budget approval before detailed feature assessment. Hidden costs such as per-API-call fees for EHR integration or per-hour charges for custom workflow configuration may emerge only during contract negotiation.

The evidence base remains thin five years after the vendor's founding. Two PubMed citations as of 2023 provide preliminary validation of behavioral health AI concepts but do not constitute large-scale effectiveness studies of the Eleos platform in real-world clinical settings. The absence of clinician-reported feedback on public forums such as Reddit's r/medicine or r/psychotherapy suggests limited adoption or a user base that does not actively engage in online professional communities. This silence contrasts with competitor tools that generate frequent discussion among clinicians evaluating ambient AI options.

EHR integration breadth remains unclear. The vendor claims EHR embedding but does not name specific supported systems or clarify whether integrations offer read-only access or bidirectional write capabilities. Practices using less common behavioral health EHRs may discover during the sales process that their system requires custom integration work at additional cost. The lack of a public compatibility matrix forces organizations to invest time in discovery calls before determining technical feasibility.

Deployment realities

EHR-embedded architecture requires coordination between the vendor's implementation team and the organization's IT department to establish secure API connections and configure single-sign-on authentication. Practices without dedicated IT staff will need to engage managed service providers or rely on the vendor's professional services team, which adds cost and extends the deployment timeline. Typical enterprise software implementations in healthcare span three to six months from contract signature to full clinician rollout, though smaller deployments may compress this timeline.

Training clinicians to trust AI-generated notes presents a change management challenge. Therapists accustomed to dictating or typing session summaries immediately after appointments must shift to reviewing and editing AI drafts, which requires confidence in the system's accuracy and clinical appropriateness. Early adopters often spend more time editing notes during the first four to six weeks as they calibrate expectations and learn the system's strengths and limitations. Organizations should budget for productivity dips during this onboarding period and provide ongoing coaching to clinicians who struggle with the workflow transition.

The voice analytics layer introduces additional complexity. Clinicians must understand which session elements the AI tracks, how analytics are calculated, and how to interpret longitudinal reports. Organizations adopting the platform for analytics-driven insights need to establish governance policies around data access, clinician training on interpretation, and protocols for acting on flagged patterns. Without clear guidelines, the analytics features risk becoming unused dashboards rather than integrated clinical tools.

Pricing realities

Eleos Health operates an enterprise-only sales model with a five-seat minimum. The vendor does not publish per-clinician monthly or annual rates, which forces prospective buyers into direct sales conversations to obtain pricing. This opacity is common in enterprise software but frustrating for organizations accustomed to transparent SaaS pricing. Practices should expect to negotiate annual contracts with limited flexibility for mid-term adjustments if clinician headcount changes.

Implementation fees likely represent a significant one-time cost. EHR integration, custom workflow configuration, and clinician training require vendor professional services hours that are billed separately from subscription fees. Organizations should budget for implementation costs equal to 20 to 40 percent of the first-year subscription cost, based on typical enterprise software deployment patterns. Ongoing support costs may also apply if the organization requires dedicated account management or priority troubleshooting.

Return on investment calculations hinge on time savings per session and clinician utilization rates. If the platform reduces post-session documentation time by 10 to 15 minutes per patient encounter and a clinician sees 20 patients per week, the annual time savings approach 150 to 220 hours. At a clinician's fully loaded hourly cost of $100 to $150, this translates to $15,000 to $33,000 in reclaimed capacity per clinician per year. Organizations should validate these assumptions with pilot deployments before committing to multi-year contracts, as actual time savings vary by practice workflow and note complexity.

Compliance + integration depth

Eleos Health holds HIPAA compliance and SOC 2 Type II attestation, which meets baseline regulatory and security requirements for handling protected health information. The absence of HITRUST certification or FDA clearance limits adoption by organizations with more stringent vendor risk assessment frameworks. Hospitals and integrated delivery networks often require HITRUST for third-party software handling clinical data, and the lack of this certification may trigger additional due diligence or disqualify the vendor from consideration during procurement.

The platform integrates with behavioral health EHRs but does not publish a list of supported systems or clarify integration depth. Some EHR connections may offer read-only access to patient demographics and appointment schedules, while others provide bidirectional write capabilities that allow the AI scribe to commit finalized notes directly to the patient record. Practices should confirm during the sales process whether their EHR is supported and whether the integration meets their workflow requirements. Custom integration work for unsupported EHRs will add cost and delay deployment.

Specialty-society endorsements are absent from publicly available information. Organizations such as the American Psychiatric Association and the American Psychological Association do not list Eleos Health among recommended technology vendors. The lack of third-party validation from professional societies may signal insufficient market penetration or an evidence base that does not yet meet the bar for formal endorsement. Practices that prioritize peer-reviewed validation or professional organization endorsements should note this gap when evaluating the platform.

Vendor stability + roadmap

Eleos Health was founded in 2020, making it a relatively young entrant in the ambient AI scribe market. The company is based in the United States, which simplifies regulatory compliance and customer support logistics for US-based practices. Publicly available information does not detail funding rounds, leadership backgrounds, or customer reference lists, which limits transparency into the vendor's financial stability and market traction. Organizations evaluating the platform should request customer references and financial health indicators during the sales process.

The vendor's roadmap priorities are not publicly disclosed. Practices considering multi-year contracts should ask about planned feature additions, EHR integration expansions, and analytics enhancements. Vendors in growth mode often prioritize new customer acquisition over feature depth, which can result in delayed updates for existing customers. Organizations should negotiate service-level agreements that include roadmap transparency and commit the vendor to delivering specific features within defined timelines.

Acquisition risk exists for any vendor founded within the past five years. Larger healthcare IT companies frequently acquire niche AI tools to expand their product portfolios, which can disrupt existing customer relationships and alter product direction. Practices should include change-of-control clauses in contracts that allow termination or renegotiation if the vendor is acquired. The absence of publicly announced acquisitions or partnerships as of early 2026 suggests the vendor remains independent, but this status can change rapidly in a consolidating market.

How it compares

Osmind offers a behavioral health EHR with integrated AI scribe functionality, which eliminates the need for third-party integrations but locks practices into the Osmind ecosystem. Practices already using Osmind should evaluate the native scribe before considering Eleos Health. Osmind's pricing is transparent and includes per-clinician monthly rates starting below the five-seat enterprise minimum that Eleos requires, making it more accessible to small practices. However, Osmind's scribe does not include the voice analytics layer that Eleos provides.

Tali AI provides a general-purpose ambient scribe with support for psychiatry and therapy sessions. Tali's pricing starts at lower per-clinician rates and does not require enterprise minimums, which makes it accessible to solo practitioners and small groups. Tali integrates with a broader range of EHRs than Eleos discloses, including primary care systems such as Epic and Cerner. However, Tali's behavioral health functionality is adapted from a primary care base rather than purpose-built for therapy workflows, and the platform does not offer voice analytics.

Suki AI and Nuance DAX represent general ambient AI scribes with large user bases across multiple specialties. Both tools support behavioral health use cases but lack the therapy-specific voice analytics that Eleos emphasizes. Suki and Nuance offer transparent pricing tiers and integrate with major EHR systems, including Epic, Cerner, and Allscripts. Practices prioritizing broad EHR compatibility and predictable pricing should evaluate these general-purpose tools before committing to a behavioral health specialist with enterprise-only sales.

Eleos Health wins when a practice prioritizes behavioral health specialization, voice analytics, and enterprise security posture over pricing transparency and small-practice accessibility. Osmind wins for practices willing to adopt a full EHR replacement. Tali wins for small practices seeking affordable ambient scribing without enterprise minimums. Suki and Nuance win for practices that value broad EHR integration and transparent pricing over behavioral health specialization.

What clinicians say

No clinician-reported feedback about Eleos Health appears on Reddit's r/medicine, r/psychotherapy, or r/psychiatry as of early 2026. This absence is notable for a tool that has been on the market since 2020 and targets a clinical specialty with active online professional communities. The lack of discussion may reflect limited adoption, a user base that does not engage in public forums, or vendor policies that discourage public commentary. Prospective buyers cannot triangulate vendor claims with independent clinician experiences shared in peer forums.

The silence contrasts with competitor tools such as Tali AI and Suki AI, which generate frequent discussion among clinicians evaluating ambient scribe options. Clinicians often share candid assessments of accuracy, workflow fit, and pricing value in these forums, and the absence of similar commentary about Eleos Health leaves a gap in the public evaluation record. Organizations considering the platform should request customer references from the vendor and conduct direct interviews with current users to gather feedback that is not available in public channels.

This evidence gap is a red flag for adoption decisions. Tools with strong market traction and satisfied user bases typically generate organic discussion in professional communities. The lack of clinician-reported feedback suggests either narrow adoption or user experiences that do not inspire proactive sharing. Organizations should treat this as a preliminary signal and investigate further before committing to multi-year enterprise contracts.

What the literature says

Two PubMed citations reference AI platforms for behavioral health as of 2023, but neither constitutes a large-scale effectiveness study of the Eleos Health platform in real-world clinical settings. The first citation, published in the Journal of Medical Internet Research in 2023, describes a randomized clinical trial evaluating an AI platform for behavioral interventions targeting depression and anxiety symptoms. The study demonstrates that AI tools can support scalable mental health care delivery and help clinicians collect objective data on patient progress. However, the paper does not name Eleos Health specifically, and the intervention described may represent a different vendor or research prototype.

The second citation, also published in JMIR Formative Research in 2023, presents a machine learning model designed to predict the assignment of therapy homework in cognitive and behavioral interventions. The study notes that greater homework compliance predicts improved treatment outcomes and that AI tools can assist therapists in tailoring assignments. The research was conducted in academic settings rather than commercial deployments, and the model's real-world applicability remains uncertain. The paper does not reference Eleos Health by name, which limits its utility as validation of the vendor's specific platform.

The thin literature base reflects the broader challenge of validating commercial AI tools in peer-reviewed journals. Vendors often lack the resources or academic partnerships required to publish large-scale effectiveness studies, and the rapid pace of product development can render published findings obsolete by the time they appear in print. Organizations evaluating Eleos Health should not interpret the limited PubMed coverage as disqualifying but should recognize that the platform lacks the rigorous evidence base that academic medical centers and evidence-driven practices prioritize when adopting clinical decision support tools.

Who it's for

Group practices with five or more clinicians in behavioral health represent the core target audience. CMIOs and practice administrators at these organizations can justify the enterprise pricing and implementation investment if the platform delivers measurable time savings and improves documentation consistency. Practices with dedicated IT support or managed service provider relationships are better positioned to handle the EHR integration and deployment logistics. Organizations already operating mature compliance programs will appreciate the HIPAA and SOC 2 Type II certifications and can absorb the vendor risk assessment workload.

Integrated delivery networks and hospital-based behavioral health divisions should evaluate Eleos Health if they seek a specialty-focused ambient scribe rather than a general-purpose tool. The voice analytics layer offers potential value for quality improvement initiatives and longitudinal outcome tracking, though the clinical validation of these features remains preliminary. Organizations willing to engage in pilot deployments and contribute feedback to the vendor's roadmap may find the platform a strategic fit, particularly if they anticipate growth in behavioral health service lines and need scalable documentation support.

Solo practitioners, small practices with fewer than five clinicians, and organizations seeking transparent pricing upfront should skip Eleos Health. The enterprise-only sales model and five-seat minimum exclude these buyers, and the lack of published pricing forces them into sales conversations that may not yield actionable information. Small practices should evaluate Tali AI or Osmind instead, both of which offer lower entry points and transparent per-clinician rates. Organizations prioritizing broad EHR compatibility and vendor maturity should consider Suki AI or Nuance DAX, which integrate with major EHR systems and serve larger user bases across multiple specialties.

The verdict

Eleos Health offers a behavioral health-specific ambient AI scribe with voice analytics and enterprise security certifications. The platform serves mid-size and large group practices willing to commit to five-seat minimums and navigate enterprise sales processes. The voice analytics layer differentiates the tool from general-purpose scribes, but the clinical validation of these features remains limited. Organizations prioritizing specialty focus and longitudinal data insights may find value in the platform, particularly if they have IT resources to manage EHR integration and change management capacity to support clinician onboarding.

The evidence gap is concerning. Two PubMed citations, zero clinician-reported feedback on public forums, and a vendor founded in 2020 without disclosed funding or customer references create adoption risk. Organizations considering Eleos Health should treat this as a preliminary-stage tool and budget for pilot deployments before committing to multi-year contracts. The lack of transparent pricing and the five-seat minimum further constrain accessibility and slow evaluation timelines. Practices accustomed to transparent SaaS pricing and freemium trials will find the enterprise sales model frustrating.

Recommended for: CMIOs at behavioral health group practices or integrated delivery networks with five or more clinicians, dedicated IT support, and tolerance for vendor immaturity. Best fit for organizations that prioritize behavioral health specialization over broad EHR compatibility and transparent pricing. Caution advised: request customer references, conduct pilot deployments, and negotiate service-level agreements that include roadmap transparency and change-of-control protections. Skip if: you operate a solo practice or small group, require transparent pricing upfront, prioritize large-scale peer-reviewed validation, or need broad EHR compatibility without custom integration work.